Hepatitis C and Tuberculosis (TB) are critical health burdens in Africa. Besides lack of available treatment, access to accurate and cost-effective diagnostic tests remain a challenge across the continent. This innovation comprises of two molecular tests for the rapid, accurate, and effective detection and load quantification of both diseases. The sensitivity and specificity of both tests are higher than current molecular test in the market, thus reducing by half the time needed to perform the PCR reaction. These innovations are 3 to 5 times less expensive than current tests in the market.